TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06549491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Wizard
Description: First, foster parents will fill out the child sleep questionnaire, which will screen for behavioral and medical sleep issues. Foster parents will then complete introductory modules focused on general sleep hygiene and education. Next, they will access tailored sleep strategy modules determined by an automated algorithm based on sleep challenges identified in the sleep screening. Participants will be notified to alert the child?s pediatrician if the screening indicates the presence of a medical sleep disorder, such as sleep disordered breathing. Participants will be asked to follow recommended sleep strategies for 2 weeks, and complete short morning daily diaries on the child?s sleep from the night prior within the Sleep Wizard platform. To reinforce intervention content and enhance adherence and integrity, participants will receive appropriately timed tailored text message reminders of strategies they should be utilizing.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep Wizard
Description: First, foster parents will fill out the child sleep questionnaire, which will screen for behavioral and medical sleep issues. Foster parents will then complete introductory modules focused on general sleep hygiene and education. Next, they will access tailored sleep strategy modules determined by an automated algorithm based on sleep challenges identified in the sleep screening. Participants will be notified to alert the child?s pediatrician if the screening indicates the presence of a medical sleep disorder, such as sleep disordered breathing. Participants will be asked to follow recommended sleep strategies for 2 weeks, and complete short morning daily diaries on the child?s sleep from the night prior within the Sleep Wizard platform. To reinforce intervention content and enhance adherence and integrity, participants will receive appropriately timed tailored text message reminders of strategies they should be utilizing.
Study: NCT06128447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZP5-9676 600 mg dose
Description: oral, chewable tablet formulation of flubendazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT06193512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SwishKit + Oral care treatment as usual
Description: SwishKit + Oral care Treatment as usual (TAU) group, instillation of chemical antimicrobial agents care and tooth brushing will be performed as in Oral Care TAU, but SwishKit care will be conducted after other oral care interventions, and prior to instillation of the chemical antimicrobial agent.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral care treatment as usual
Description: Oral care will be delivered per standard operating procedure of the ICU, which may include the instillation of chemical agents for the purpose of reducing bacterial load, will be administered at 4-hour intervals, and tooth brushing performed twice daily (morning and evening).
Study: NCT06103032

Intervention type: PROCEDURE
Intervention: Breast Conserving Surgery
Description: Patients undergoing breast conserving surgery

Intervention type: PROCEDURE
Intervention: Mastectomy
Description: Patients undergoing mastectomy
Study: NCT06170398

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Wideband tympanometry
Description: Wideband tympanometry

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electrocochleography
Description: Electrocochleography

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vestibular Evoked Myogenic potentials
Description: Vestibular Evoked Myogenic potentials
Study: NCT03495986

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: An individualized, detailed dietary plan consistent with My Healthy Plate Dietary Guidelines of America will be followed under supervision of Registered Dietitian with weekly telemedicine conferences and monitored dietary intake via MyFitnessPal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: An individualized, detailed dietary plan consistent with My Healthy Plate Dietary Guidelines of America will be followed under supervision of Registered Dietitian with weekly telemedicine conferences and monitored dietary intake via MyFitnessPal.
Study: NCT05088278

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical single bundle ACL reconstruction with hamstrings
Description: Anatomical ACL reconstruction with quadruple-bundle hamstrings graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical single bundle ACL reconstruction with patellar tendon
Description: Anatomical single bundle ACL reconstruction with patellar tendon

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with over the top plus lateral plasty technique
Description: Non-anatomical ACL reconstruction, the hamstrings' tibial insertion is preserved; a double-bundle hamstring graft is passed intra-articularly, fixed in over the top position on the lateral femoral condyle, and then passed extra-articularly deeply to ileo-tibial band up to the tibia, where it is fixed at the level of Gerdy's tubercle.
Study: NCT05691855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-NY009
Description: Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY009
Study: NCT05489978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cervical Cancer Stigma Reduction Intervention
Description: Change in knowledge:~Cervical cancer burden in Nepal, signs and symptoms, preventive measures available, lifestyle modifications, HPV vaccination, early diagnosis, screening, and treatment.~Change in Stigma~1. Para-social contact~   * Video of a person facing cervical cancer what symptoms she got, how she dealt with it, and how she overcame it.~  * Experiences of a cervical cancer survivor so that women personalize the information by relating it to their own life experiences by changing their attitude and behavior.~2. Participatory learning techniques~   * Personal stories: Voluntary self-reflection of any stigma they perceive on cervical cancer or their community perceives cervical cancer.~  * Group Discussion: Discuss the drivers of stigma, facilitators of sigma, types of stigma prevalent in your community, and consequences of stigma.~3. Myths vs facts: Negative attitudes, myths, and misconceptions about cervical cancer will be contraindicated by factual information.
Study: NCT06062862

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Incentive Spirometer
Description: Tri-flow device flow-oriented incentive spirometer .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The breather respiratory muscle training device
Description: The breather respiratory muscle training device which allows for adjustable levels of resistance using easy-to-read dials, which allows to adjust the device to the settings require
Study: NCT04850209

Intervention type: OTHER
Group type: OTHER
Intervention: oral and written education
Description: oral and written education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral and written education
Description: oral and written education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wechat group
Description: Wechat group: oral and written education plus Wechat group based interactive education provided by medical professional
Study: NCT06447467

Intervention type: DIAGNOSTIC_TEST
Intervention: pro BNP
Description: Test is mainly used to help diagnose or rule out heart failure in a person who is having symptoms

Intervention type: DIAGNOSTIC_TEST
Intervention: pro BNP
Description: Test is mainly used to help diagnose or rule out heart failure in a person who is having symptoms
Study: NCT04904458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group (enfacement illusion)
Description: Virtual reality enfacement illusion exposure

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group (Pleasant virtual environment exposure)
Description: Pleasant virtual environment exposure
Study: NCT05498688

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low carbohydrate
Description: Participants will have a low carbohydrate meal
Study: NCT06304454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Board game intervention
Description: 5 weeks / 2 sessions each week / 1 hour each session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Board game intervention
Description: 5 weeks / 2 sessions each week / 1 hour each session
Study: NCT05864976

Intervention type: DEVICE
Intervention: Support Vector Machine
Description: Machine learning algorithm
Study: NCT06251232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Placebo
Study: NCT05713643

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB Technique
Description: The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral to the spinous procedure of T8 to obtain a parasagittal view. An echogenic needle will be introduced from the caudal end of the probe and advanced in-plane direction until the needle tip hit the tip of the transverse process. Bupivacaine will be afterwards injected into the erector spinae plane block. Linear spread cranially and caudally below the muscle upon injection will be visualized on the US screen indicating successful block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TPVB Technique
Description: The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral and parallel to 8th spinous process till transverse process, superior costotransverse ligament, and pleura will be visualized then lateral tilt of the probe was done for better visualization of the PVS between the superior costotransverse ligament and the pleura. An echogenic needle was introduced at caudal end of transducer using the in-plane technique till piercing the superior costotransverse ligament . Bupivacaine will be injected into the PVS with downward displacement of the pleura indicating a successful block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QLB Technique
Description: The patient will be in lateral position. The probe will be placed above the iliac crest. The Petit's triangle will be identified. The three abdominal muscles (i.e., the external oblique, internal oblique and transversus abdominus muscles) will be detected. Both the external oblique and internal oblique muscles will be followed posteriorly until the layers of the thoracolumbar fascia appear as a bright hyperechogenic line. The quadratus lumborum muscle appears below to the latissimus dorsi muscle. While performing the quadratus lumborum block, Shamrock sign is identified; the transverse process of L4 appears as a stem whereas the three muscles psoas muscle, quadratus lumborum muscle and erector spinae appear as the leaves. A 22G (50mm) needle was inserted using an in-plane technique along the posterior edge of the ultrasound probe in the anteromedial direction. The needle tip was placed between the quadratus lumborum muscle and the Erector spinae muscle.
Study: NCT06233370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity walking exercise
Description: For each intervention arm, participants will be walking at a moderate intensity, determined based on a step rate of approximately 100 steps per minute (measured by a Fitbit)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity walking exercise
Description: For each intervention arm, participants will be walking at a moderate intensity, determined based on a step rate of approximately 100 steps per minute (measured by a Fitbit)
Study: NCT05329077

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulsenmore ES home ultrasound device
Description: Pregnant participants will use Pulsenmore ES device to assess the safety and the efficacy of the device in monitoring fetal parameters
Study: NCT06159595

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intracranial electrodes
Description: Surgically-implanted intracranial electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intracranial electrodes
Description: Surgically-implanted intracranial electrodes.
Study: NCT04955392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment protocol
Description: The intervention protocol consists of 4 techniques that will be performed according to the following order:~1. Inhibition of the suboccipital muscles.~2. Parietal Lift.~3. Sutherland Technique of Sphenobasilar Synchondrosis.~4. Compression technique of the fourth ventricle (CV4).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham technique
Description: Sham technique that consists of placing the hands on top of the skull without any therapeutic intention for five minutes.
Study: NCT04819737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SC MRI
Description: SC MRI (Averaged Magnetization Inversion Recovery Acquisitions (AMIRA), standard conventional SC MRI sequences, additional sequences for spinal cord MRI (sagittal-2D or 3D short tau inversion recovery, sagittal-2D or 3D phase-sensitive inversion recovery, 3D magnetization prepared 2 rapid acquisition gradient echoes (MPRAGE)). To evaluate the presences of ongoing inflammation (acute or chronic) in the SC of patients, 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) will be acquired.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient questionnaire
Description: 12-item multiple sclerosis walking scale (MSWS-12) questionnaire: self-report measure of the impact of MS on the individual's walking ability
Study: NCT04953312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: blood

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: blood

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: blood
Study: NCT05879783

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy
Description: After intravenous injection of fluorescein sodium, pCLE-based optical biopsy will be performed.
Study: NCT05389878

Intervention type: OTHER
Intervention: rehabilitation
Description: All patients addressing intemsive inpatient post stroke rehabilitation undergo a shared evidence based Integrated Care pathway that is routinely adopted in all the participating Centres
Study: NCT06093061

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CCRT with Maintenance Tislelizumab and Metronomic Capecitabine
Description: CCRT: Radiotherapy will be delivered once daily, for 5 days per week, over 6 to 7 weeks. During RT, cisplatin will be administered either 100 mg/m2 3-weekly or 40 mg/m2 weekly, IV infusion (physician's choice).~Maintenance: Tislelizumab 200mg, day 1 per 3-week cycle, intravenous (IV) infusion and capecitabine 650 mg/m2, days 1-21 per 3-week cycle, bidaily, oral, for a total of 12 months (17 cycles).
Study: NCT06264115

Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: Using Three Ports or Four Ports for Laparoscopic Cholecystectomy

Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: Using Three Ports or Four Ports for Laparoscopic Cholecystectomy
Study: NCT05898958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic paravertebral block
Description: The block will be performed in the lateral position.After skin sterilization,the ultrasound transducerprobe (6-13-MHz high-frequency linear transducer) is positioned in the vertical plane ∼2.5 cm lateral tomarked spinous process with its orientation directedcranially. T.After local anesthetic infiltration, an 18-gauge Tuohy needle will be inserted into the paravertebral spacein an 'in plane' technique. After a negativeaspiration through the needle, 20 ml of 0.25%bupivacaine with 1: 200 000 epinephrine will be injected slowly over 3 min.A20-G epidural catheter will be threaded through Tuohyneedle and advanced 2-3 cm into the paravertebral space.Anyprocedure-related adverse effects will be noted, and thedermatomal loss of pin prick sensation will be testedover both sides.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rhomboid intercostal and subserratus block
Description: The ultrasound probe will be placed in the obliquesagittal plane orientation, 1-2 cm medial to the medial scapula at theT5-T6 level. The trapezius muscle, rhomboid major muscle, ribs, intercostal muscle and pleura will be visualized respectively using ultrasound.After local anesthetic infiltration, needle will be inserted from the cranial to the caudal direction using the in-plane technique. The needle will be advanced between the rhomboid major and intercostal muscle fascia. The location of the needle will be confirmed with 2 mL saline solution, 10 ml of 0.25% bupivacaine with 1 : 200 000 epinephrine will beinjected slowly over 3min.for the subserratus block 10 ml of 0.25%bupivacaine with 1 : 200 000 epinephrine will be injected betweenthe serratus and intercostal muscle fascia at level of t9.
Study: NCT04979507

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uninterrupted sleep followed by functional neuroimaging.
Description: 2 within-subject sleep conditions: uninterrupted sleep; selective REM sleep reduction, followed by functional neuroimaging with emotion reactivity and regulation tasks the following morning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uninterrupted sleep followed by functional neuroimaging.
Description: 2 within-subject sleep conditions: uninterrupted sleep; selective REM sleep reduction, followed by functional neuroimaging with emotion reactivity and regulation tasks the following morning
Study: NCT05097807

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smartphone related behaviors
Description: Participants are required to watch specific contents on their own smartphones.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smartphone related behaviors
Description: Participants are required to watch specific contents on their own smartphones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smartphone related behaviors
Description: Participants are required to watch specific contents on their own smartphones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smartphone related behaviors
Description: Participants are required to watch specific contents on their own smartphones.
Study: NCT05928455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: Experimental: The LYB001 vaccine was administered through intramuscular injection at doses of 30ug or 60ug in a 0.5mL volume.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac
Description: Active Comparator: The CoronaVac vaccine was administered through intramuscular injection in a 0.5mL volume.
Study: NCT05453617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The 5:2 diet
Description: Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
Study: NCT05185609

Intervention type: OTHER
Intervention: Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS
Description: Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.

Intervention type: OTHER
Intervention: Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS
Description: Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.

Intervention type: OTHER
Intervention: Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS
Description: Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.

Intervention type: OTHER
Intervention: Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS
Description: Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.

Intervention type: OTHER
Intervention: Exposure 2: Changes in anorectal motor function or compliance.
Description: Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.

Intervention type: OTHER
Intervention: Exposure 2: Changes in anorectal motor function or compliance.
Description: Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.

Intervention type: OTHER
Intervention: Exposure 2: Changes in anorectal motor function or compliance.
Description: Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.

Intervention type: OTHER
Intervention: Exposure 2: Changes in anorectal motor function or compliance.
Description: Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
Study: NCT05738850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-932
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-932
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-932
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-932
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-932
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule